{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.77","value":"-0.46"},{"groupId":"OG001","spread":"2.08","value":"-0.23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received ibrutinib 420 milligram (mg) (3 \\* 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.","id":"OG000","title":"Ibrutinib+BR"},{"description":"Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo+BR"}],"paramType":"MEAN","populationDescription":"ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"Baseline to EOT (Up to 2 years)","title":"Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)","type":"SECONDARY","unitOfMeasure":"milligram per liter (mg/L)"}